Figure 6.

Preventive treatment of mice with allergen‐specific virus‐like nanoparticles (VNP). A, Scheme for preventive treatment and challenge of mice in B‐C. B, Art v 1‐specific serum IgE levels (day 63) of TCR/DR1 mice i.n. prophylactically treated with MA::Art v 1 VNP, Art v 1:: glycosylphosphatidylinositol (GPI) VNP, empty VNP, or PBS and challenged as indicated. C, Cytokines produced by lung homogenates of mice (day 63) upon restimulation with aqueous mugwort pollen extract (100 μg/mL for 72 h). D, Scheme of respiratory exposure and challenge protocol. E, Relative numbers of CD3⁺ CD4⁺Foxp3⁺ cells in lung homogenates and F, lung resistance of mice prophylactically treated and challenged as in D. Data show the summary (B‐C) of 13 (except four for PBS) mice per group of three (except one for PBS) independent experiments or the summary (E) of 10 (except nine for empty VNP and PBS) mice of two independent experiments. F shows the summary of 15 (except 14 for PBS, 13 for empty particles, and 8 for Art v 1::GPI) mice of three independent experiments (except two for Art v 1::GPI). Only significant differences are indicated. One‐way ANOVA followed by Holm's Sidak correction. *P<0.05; **P<0.01